[A20-123] Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V
Last updated 01.04.2021
Project no.:
A20-123
Commission:
Commission awarded on 17.12.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy
Result of dossier assessment:
Hint of non-quantifiable added benefit
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.